Curis, Inc. (CRIS) Announces U.S. Patent Issuance Strengthening Intellectual Property Position of PI3K-HDAC Inhibitor CUDC-907
6/20/2013 8:58:32 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LEXINGTON, Mass., June 20, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of various cancers, today announced the issuance of U.S. Patent No. 8,461,157, which claims methods of treating human diseases or disorders mediated by one or more of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and histone deacetylase (HDAC) proteins, using compounds from a genus of small molecules with dual inhibitory properties, including but not limited to CUDC-907, a proprietary clinical stage dual inhibitor of PI3K and HDAC enzymes. This patent, along with another related patent issued in February 2013 (U.S. Patent No. 8,367,663), significantly enhances the intellectual property portfolio for Curis' proprietary chemical entities that target PI3K and HDAC, and in some instances mTOR, within a single molecule for the treatment of certain human diseases.
Help employers find you! Check out all the jobs and post your resume.
comments powered by